Referring Clinician
Please email all referrals to CentralReferral@adhb.govt.nz (including Att: ACTC in email subject)
Email us for any other queries: infoACTC@adhb.govt.nz
| Tumour Stream | Trial Name | Study Description | Key Investigational Agent | Key Inclusion Criteria | Recruitment Status |
|---|---|---|---|---|---|
| All Cancers | Beigene SMAC mimetic BGB-24714-101 | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Smac Mimetic BGB-24714 as Monotherapy and in Combination With Chemotherapy in Patients With Advanced Solid Tumors | BGB-24714 (SMAC mimetic) +/- paclitaxel | • Measurable disease • ECOG PS 0-1 • Adequate organ function | Open |
| All Cancers | BGB-15025 and Tislelizumab in advanced solid tumours | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination with Anti-PD- 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors | BGB-15025 (oral HPK1 inhibitor) +/- tislelizumab | • Measurable disease • Must have biopsiable disease or archival tissue • ECOG PS 0-1 • Adequate organ function • No history of autoimmune disorders (please discuss with investigators) | Open |
| All Cancers | Genentech GO42144 KRAS | Genentech, Inc. Dose-Expansion study, Evaluating The Safety, Pharmacokinetics, And Activity Of GDC-6036 In Patients With Advanced Solid Tumors With A KRAS G12C Mutation (GO42144) | Multiple arm study -GO42144 (KRAS G12C inhibitor) +/- various IMP (please discuss with investigator team) | • At least 2L treatment • Measurable disease • Biopsiable disease • ECOG PS 0-1 • Adequate organ function | Open |
| All Cancers | Roche/Genentech GO43712 study | A Phase Ib, Multicenter, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC 1971 in Combination with Atezolizumab in Patients with Advanced or Metastatic Solid Tumors. | GDC 1971 (oral SHP2 inhibitor) | • At least 2L treatment • Measurable disease • Biopsiable disease • ECOG PS 0-1 • Adequate organ function | Project site in setup |
| All Cancers | TAPISTRY BO41932 | Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational For You (TAPISTRY) Phase II Platform Trial | • ALK – Alectinib • NTRK 1/2/3 - entrectinib • ROS – entrectinib • TMB high – atezolizumab • PIK3CA – inavolisib • RET -praseltinib (AKT, MDM2, HER2, BRAF arms closed) | • At least 2L treatment or no acceptable treatment • Measurable disease • Must have archival tissue or biopsiable disease for NGS testing (FNA not allowed) • ECOG PS 0-1 • Adequate organ function • NSCLC not allowed for ALK/ROS arms | Open |
| All Cancers | The Cancer Molecular Screening and Therapeutics (MoST) Program | The Cancer Molecular Screening and Therapeutics (MoST) Program - A framework protocol for multiple, parallel, signal-seeking clinical studies of novel molecularly targeted therapies for patients with advanced cancer and unmet clinical need. | No therapeutic arm at present | • Certain tumour types accepted - please discuss with investigator team • CtDNA available | Open |
| Breast/GI | APEC | Does the Concomitant Administration of Proton Pump Inhibitors Affect Capecitabine Pharmacokinetics? – A Prospective, Single-Centre, Two-Arm, Randomised, Unblinded, Cross-Over Bioequivalence Study of Capecitabine With or Without Concomitant Pantoprazole. | Pantoprazole | • At least 2 cycles of single agent capecitabine • CAPOX not permitted. | Open |
| Colorectal | BREAKWATER | Open label phase 3 trial of first-line encorafenib plus cetuximab with or without chemotherapy versus standard of care therapy in participants with metastatic BRAFV600E mutant colorectal cancer | Encorafenib + cetuximab +/- chemotherapy | • BRAF V600E mutant • Measurable disease • ECOG PS 0-1 • Adequate organ function • Treatment naïve in metastatic setting | Open |
| Gastrointestinal | CITRON | Reducing Oxaliplatin Neurotoxicity: A Phase 1B Randomized, Double-Blind, Placebo- Controlled, Crossover, Dose-Finding and Proof-of-Concept Trial of Cimetidine in Gastrointestinal Cancer Patients | Cimetidine | • At least 2 cycles of oxaliplatin-based chemotherapy • Must not have pre-existing >G1 peripheral neuropathy | Open |
| Head and Neck | Tarlox study | Window of opportunity trial of Tarloxotinib combined with SBRT in advanced HPV negative head & neck cancer | Tarloxitinib +/- SBRT | • P16 negative SCC • Stage III/IV • Primary cancer must be seen on CT | Open |
| Lymphoma | BGB-11417-101 | A Phase 1/1b Open-Label Dose Escalation and Expansion Study of the Bcl-2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib (BGB-3111) in Patients With Mature B-Cell Malignancies | Open | ||
| Lymphoma | NP30179 | A multicenter, open-label, phase 1 study to evaluate the safety, efficacy, tolerability and pharmacokinetics of escalating doses of RO7082859 as a single agent and in combination with obinutuzumab administered after a fixed, single dose pre-treatment of obinutuzumab (Gazyva/Gazyvaro) in patients with relapsed/refractory B-cell non-hodgkin's lymphoma | Open | ||
| NSCLC/ H+N SCC | BGB-OX40 | Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti-OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | BGB-A445 (IV OX40 agonist) +/- tislelizumab | • Progression on at least 1L Rx (up to 3L allowed) • Measurable disease • Biopsiable disease • ECOG PS 0-1 • Adequate organ function • No concurrent steroids (> 10 mg prednisone) • No hx of autoimmune disorders (please discuss with investigators) | Open |
| NSCLC/H+N SCC | BGB-900-105 | Phase 1/1b Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors | BGB-A1217 (anti TIGIT antibody) + tislelizumab - | • Treatment naïve • PDL1 + (TC > 1% for NSCLC, vCPS > 1% for H+N SCC) • Measurable disease • Must have archival tissue or biopsiable disease • ECOG PS 0-1 • Adequate organ function • No concurrent steroids (> 10 mg prednisone) • No hx of autoimmune disorders (please discuss with investigators) | Open |
| Prostate | MK-365 | Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) | Currently open – pembrolizumab + lenvatinib (both AC, NET) , pembrolizumab + carboplatin + etoposide (NET) | • Adenocarcinoma, neuroendocrine • Biopsiable disease from non-irradiated site (bone allowed for certain cohorts) • Prior anti PD1/PDL1, radiopharmaceuticals, superscan not permitted. | Open |
| Renal | ICON Exelixis XL092-002 Stellar 002 | Phase 1b dose escalation and expansion study with our new TKI combined with Nivolumab, Nivolumab/Ipilimumab or Nivolumab/BEMPEG | Project site in setup |